Medication noncompliance: another iceberg???s tip
- 1 March 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (5) , 776-778
- https://doi.org/10.1097/01.tp.0000110409.71847.6f
Abstract
After renal transplantation, immunosuppressive medications must be taken long-term to avoid acute rejection and the cascade of events leading to "chronic allograft dysfunction" and loss. In the past, when posttransplant immunosuppression was limited to azathioprine and prednisone, acute rejection episodes were common, and it was difficult to identify the impact of medication noncompliance. However, with more potent and effective drugs, acute rejection is uncommon, and medication noncompliance emerges as an increasingly important factor in the outcome of solid-organ transplantation. Recent studies have clearly demonstrated that medication noncompliance leads to an increased incidence of acute rejection, chronic rejection, and graft loss. Today, although a number of questions remain unanswered, new methodologies, such as electronic monitors, provide opportunities to study medication noncompliance and its risk factors, and the potential for earlier intervention to improve clinical outcomes.Keywords
This publication has 7 references indexed in Scilit:
- Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic reviewTransplantation, 2004
- Noncompliance postrenal transplantation: measuring the extent of the problem using electronic surveillance and nurse practitioner interviewsTransplantation Proceedings, 2002
- Maintenance immunosuppression in the renal transplant recipient: An overviewAmerican Journal of Kidney Diseases, 2001
- The natural history of azathioprine compliance after renal transplantationKidney International, 2001
- Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agentsPharmacoepidemiology and Drug Safety, 1999
- Drug Compliance in Therapeutic Trials: A ReviewControlled Clinical Trials, 1998